I think it also important to keep in mind Jon's comments on this topic on the last 3 webinars including late last year. He is a charted accountant and was the CFO of Neuren before stepping up to be CEO. It is possible he was aware of the NZ tax losses at that time and there other factors. Our R&D spend has increased by our SG&A is stable. Our R&D spend has tax offsets/credits applied (selectively) so it can further reduce the amount of corproate tax we would otherwise have had paid simply by calculating our revenue against our costs as per the half yearly report.
Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome, page-29
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.280(2.28%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.52 | $12.73 | $12.26 | $8.152M | 652.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 665 | $12.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.55 | 235 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |